Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million

Core Insights - Bioventus Inc. reported a fourth-quarter adjusted EPS of 15 cents, an increase from 7 cents, surpassing the consensus estimate of 8 cents [1] - The company achieved sales of $153.6 million, reflecting a year-over-year growth of 13.5%, exceeding the consensus of $145.2 million, driven by strong performance in pain treatments and surgical solutions [1] Sales Performance - Pain treatment sales rose by 18.7% to $62.8 million, while Surgical Solutions sales increased by 16.8% to $46.43 million; however, Restorative Therapies sales saw a slight decline of 0.6% to $25.95 million [2] - The net loss from continuing operations was reduced to $0.3 million from $7.7 million a year ago, indicating improved financial health [2] - Adjusted EBITDA from continuing operations reached $28.3 million, a 28.3% increase from $22.0 million last year, attributed to strong revenue growth and expanded adjusted gross margins [2] Financial Position - The company improved its balance sheet by reducing long-term debt by $48.3 million, enhancing liquidity [3] Future Guidance - Bioventus anticipates 2025 sales between $560 million and $570 million, compared to a consensus of $554.62 million, indicating an organic growth of approximately 6.1% to 8.0% when accounting for the divestiture of its Advanced Rehabilitation Business, which generated $45.4 million in revenue in 2024 [4] - The expected adjusted EPS for 2025 is projected to be between $0.64 and $0.68, exceeding Street estimates of $0.55 [4] - Adjusted EBITDA is forecasted to be between $112 million and $116 million, reflecting a 100 basis points increase in Adjusted EBITDA Margin compared to 2024 [5] Stock Performance - Following the earnings report, BVS stock increased by 21.9%, reaching $10.68 [5]